Christopher Ma

Christopher Ma

Auto-generated profile, based on publicly available information

Christopher Ma

Division of Gastroenterology & Hepatology, Department of Medicine, Cumming School of Medicine, University of Calgary , Calgary, Alberta

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2017 in American Journal of Gastroenterology
Verified
Journal Article
Open access
PDF file
CMChristopher Ma
Christopher Ma
GMGordon W. Moran
Gordon W. Moran
EBEric I Benchimol
Eric I Benchimol
LTLaura E Targownik
Laura E Targownik
SHSteven J Heitman
Steven J Heitman
GKGilaad Kaplan
Gilaad Kaplan
Temporal changes for intestinal resections for Crohn’s disease (CD) are controversial. We validated administrative database codes for CD diagnosis and surgery in hospitalized patients and then evaluated temporal trends in CD surgical resection rates. First, we validated International Classification of Disease (ICD)-10-CM coding for CD diagnosis in hospitalized patients and Canadian Classification of Health Intervention coding for surgical resections. Second, we used these validated codes to conduct population-based surveillance between fiscal years 2002 and 2010 to identify adult CD patients undergoing intestinal resection (n=981). Annual surgical rate was calculated by dividing incident surgeries by estimated CD prevalence. Time trend analysis was performed and annual percent change (APC) with 95% confidence intervals (CI) in surgical resection rates were calculated using a generalized linear model assuming a Poisson distribution. In the validation cohort, 101/104 (97.1%) patients undergoing surgery and 191/200 (95.5%) patients admitted without surgery were confirmed to have CD on chart review. Among the 116 administrative database codes for surgical resection, 97.4% were confirmed intestinal resections on chart review. From 2002 to 2010, the overall CD surgical resection rate was 3.8 resections per 100 person-years. During the study period, rate of surgery decreased by 3.5% per year (95% CI: −1.1%, −5.8%), driven by decreasing emergent operations (−10.1% per year (95% CI: −13.4%, −6.7%)) whereas elective surgeries increased by 3.7% per year (95% CI: 0.1%, 7.3%). Overall surgical resection rates in CD are decreasing, but a paradigm shift has occurred whereby elective operations are now more commonly performed than emergent surgeries.

2 March 2017 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
CMC. Ma
C. Ma
RFR. N. Fedorak
R. N. Fedorak
GKG. G. Kaplan
G. G. Kaplan
LDL. A. Dieleman
L. A. Dieleman
SDS. M. Devlin
S. M. Devlin
RPR. Panaccione
R. Panaccione
Summary: Background: Ustekinumab is a monoclonal antibody targeting interleukins‐12 and ‐23, with efficacy in Crohn's disease (CD) demonstrated in clinical trials.Aim: To assess the real‐world clinical, endoscopic and radiographic response and remission outcomes achieved with ustekinumab in medically‐refractory CD.Methods: A retrospective multicentre cohort study was performed on CD patients receiving ustekinumab between 2011 and 2016. The primary outcome was achievement of clinical and objective steroid‐free response and remission at 3, 6 and 12 months. Clinical response and remission were defined by reduction in Harvey Bradshaw Index (HBI) of ≥3 points and an HBI ≤4 points respectively. Objective response was defined by improvement in endoscopic or radiographic CD, as assessed by ileocolonoscopy, contrast‐enhanced ultrasound or CT/MR enterography. Objective remission was defined by endoscopic mucosal healing or complete resolution of inflammatory parameters on radiographic assessment.Results: A total of 167 CD patients were treated with ustekinumab. 95.2% (159/167) previously failed anti‐TNF therapy. Median follow‐up was 45.6 weeks (IQR: 24.4–88.9). At 3 months, clinical response was achieved in 38.9% (65/167) and remission in 15.0% (25/167) of patients. At 6 months, clinical response was achieved in 60.3% (91/151) and remission in 25.2% (38/151) of patients. At 12 months, clinical response was achieved in 59.5% (66/111) and remission in 27.9% (31/111) of patients. Endoscopic or radiographic response was demonstrated in 54.5% (67/123) at 6 months and 55.8% (48/86) of patients at 12 months.Conclusions: Ustekinumab is an effective therapeutic option for inducing and maintaining clinical, endoscopic and radiographic response in patients with Crohn's disease failing anti‐TNF therapy.

18 November 2021 in Inflammatory Bowel Diseases
Verified
Journal Article
Open access
PDF file
LTLester Tsai
Lester Tsai
JMJeffrey D McCurdy
Jeffrey D McCurdy
CMChristopher Ma
Christopher Ma
VJVipul Jairath
Vipul Jairath
SSSiddharth Singh
Siddharth Singh
Background and Aims: Perianal Crohn’s disease (pCD) is a potentially severe phenotype of CD. We conducted a systematic review with meta-analysis to estimate cumulative incidence, risk factors, and outcomes of pCD in population-based cohort studies. Methods: Through a systematic literature review through March 1, 2021, we identified population-based inception cohort studies reporting cumulative incidence of perianal disease (primarily abscess and/or fistula) in patients with CD. We estimated the cumulative incidence of pCD at presentation and 1-, 5-, and 10-year follow-up, and risk factors for perianal disease and outcomes including risk of major (bowel resection, proctectomy, ostomy) and minor perianal (incision and drainage, seton placement, etc.) surgery. Results: In 12 population-based studies, prevalence of pCD was 18.7% (95% confidence interval [CI], 12.5%-27.0%) with 1-, 5-, and 10-year risk of perianal disease being 14.3% (95% CI, 7.9%-24.6%), 17.6% (95% CI, 11.3%-26.5%), and 18.9% (95% CI, 15.0%-23.4%), respectively. Approximately 11.5% of patients (95% CI, 6.7%-19.0%) had perianal disease at or before CD diagnosis. Colonic disease location and rectal involvement were associated with higher risk of pCD. Overall, 63.3% of patients (95% CI, 53.3-72.3) required minor perianal surgery and 6.4% of patients (95% CI, 1.8%-20.6%) required major abdominal surgery for pCD. Use of biologic therapy for pCD is common and has steadily increased throughout the years. Conclusions: Approximately 1 in 5 patients with CD develops perianal disease within 10 years of CD diagnosis, including 11.5% who have perianal disease at presentation. Approximately two-thirds of patients require perianal surgery, with a smaller fraction requiring major abdominal surgery.

1 November 2011 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
SSShanika de Silva
Shanika de Silva
CMChristopher Ma
Christopher Ma
MPMarie–Claude Proulx
Marie–Claude Proulx
MCMarcelo Crespin
Marcelo Crespin
BKBelle S. Kaplan
Belle S. Kaplan
GKGilaad Kaplan
Gilaad Kaplan

1 May 2017 in Inflammatory Bowel Diseases
Verified
Journal Article
Closed access
PDF file
CMChristopher Ma
Christopher Ma
RFRichard N. Fedorak
Richard N. Fedorak
GKGilaad G. Kaplan
Gilaad G. Kaplan
LDLevinus A. Dieleman
Levinus A. Dieleman
SDShane M. Devlin
Shane M. Devlin
RPRemo Panaccione
Remo Panaccione
Background. Ustekinumab is a monoclonal antibody targeting interleukins 12 and 23. While effective in clinical trials for Crohn's disease (CD), long-term maint

26 September 2024 in New England Journal of Medicine
Verified
Journal Article
Closed access
BSBruce E. Sands
Bruce E. Sands
BFBrian G. Feagan
Brian G. Feagan
LPLaurent Peyrin-Biroulet
Laurent Peyrin-Biroulet
SDSilvio Danese
Silvio Danese
DRDavid T. Rubin
David T. Rubin
STStephan Targan
Stephan Targan
Tulisokibart is a tumor necrosis factor-like cytokine 1A (TL1A) monoclonal antibody in development for the treatment of moderately to severely active ulcerative colitis. A genetic-based diagnostic test was designed to identify patients with an increased likelihood of response. We randomly assigned patients with glucocorticoid dependence or failure of conventional or advanced therapies for ulcerative colitis to receive intravenous tulisokibart (1000 mg on day 1 and 500 mg at weeks 2, 6, and 10) or placebo. Cohort 1 included patients regardless of status with respect to the test for likelihood of response. Cohort 2 included only patients with a positive test for likelihood of response. The primary analysis was performed in cohort 1; the primary end point was clinical remission at week 12. Patients with a positive test for likelihood of response from cohorts 1 and 2 were combined in prespecified analyses. In cohort 1, a total of 135 patients underwent randomization. A significantly higher percentage of patients who received tulisokibart had clinical remission than those who received placebo (26% vs. 1%; difference, 25 percentage points; 95% confidence interval [CI], 14 to 37; P<0.001). In cohort 2, a total of 43 patients underwent randomization. A total of 75 patients with a positive test for likelihood of response underwent randomization across both cohorts. Among patients with a positive test for likelihood of response (cohorts 1 and 2 combined), clinical remission occurred in a higher percentage of patients who received tulisokibart than in those who received placebo (32% vs. 11%; difference, 21 percentage points; 95% CI, 2 to 38; P = 0.02). Among all the enrolled patients, the incidence of adverse events was similar in the tulisokibart and placebo groups; most adverse events were mild to moderate in severity. In this short-term trial, tulisokibart was more effective than placebo in inducing clinical remission in patients with moderately to severely active ulcerative colitis. (Funded by Prometheus Biosciences, a subsidiary of Merck; ARTEMIS-UC ClinicalTrials.gov number, NCT04996797.).